Ningbo David Medical Device Co., Ltd. (SHE:300314)
China · Delayed Price · Currency is CNY 11.53
-0.07 (-0.60%)
Sep 4, 2026, 3:04 PM CST
SHE:300314 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,321 | 3,623 | 3,243 | 4,360 | 3,738 | 3,917 | |
Market Cap Growth | -19.48% | 11.72% | -25.63% | 16.64% | -4.56% | -17.22% |
Enterprise Value | 2,729 | 3,034 | 2,630 | 3,611 | 3,072 | 3,316 |
Last Close Price | 11.53 | 12.50 | 11.11 | 14.69 | 12.50 | 12.95 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 55.62 | 41.62 | 56.63 | 29.54 | 38.40 | 48.83 |
Forward PE | - | 16.08 | 16.08 | 18.13 | 40.84 | 40.84 |
PS Ratio | 5.68 | 6.20 | 6.15 | 7.05 | 7.39 | 8.26 |
PB Ratio | 2.70 | 2.94 | 2.78 | 3.75 | 3.53 | 3.95 |
P/TBV Ratio | 2.79 | 3.05 | 2.89 | 3.91 | 3.70 | 4.07 |
P/FCF Ratio | 61.58 | 105.87 | - | 45.99 | 60.50 | 87.14 |
P/OCF Ratio | 34.29 | 40.59 | 34.55 | 32.25 | 33.51 | 76.08 |
PEG Ratio | - | 0.67 | 0.67 | 0.67 | 0.67 | 0.67 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.67 | 5.20 | 4.99 | 5.84 | 6.07 | 6.99 |
EV/EBITDA Ratio | 33.02 | 32.81 | 31.06 | 23.36 | 28.20 | 36.95 |
EV/EBIT Ratio | 46.66 | 42.70 | 43.56 | 28.38 | 35.93 | 50.54 |
EV/FCF Ratio | 50.60 | 88.66 | - | 38.09 | 49.71 | 73.78 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Debt / EBITDA Ratio | 0.06 | 0.06 | 0.10 | 0.09 | 0.13 | 0.01 |
Debt / FCF Ratio | 0.08 | 0.18 | - | 0.14 | 0.24 | 0.01 |
Net Debt / Equity Ratio | -0.48 | -0.54 | -0.57 | -0.67 | -0.69 | -0.69 |
Net Debt / EBITDA Ratio | -7.37 | -7.18 | -7.87 | -5.03 | -6.68 | -7.65 |
Net Debt / FCF Ratio | -10.98 | -19.40 | 14.55 | -8.21 | -11.77 | -15.28 |
Asset Turnover | 0.41 | 0.40 | 0.38 | 0.47 | 0.42 | 0.42 |
Inventory Turnover | 1.37 | 1.42 | 1.37 | 1.71 | 1.47 | 1.53 |
Quick Ratio | 2.78 | 2.85 | 3.04 | 4.15 | 4.32 | 4.38 |
Current Ratio | 3.99 | 3.71 | 3.88 | 5.03 | 5.23 | 5.28 |
Return on Equity (ROE) | 4.95% | 7.25% | 4.91% | 13.28% | 9.50% | 8.25% |
Return on Assets (ROA) | 2.53% | 3.06% | 2.71% | 6.06% | 4.44% | 3.60% |
Return on Invested Capital (ROIC) | 8.29% | 11.71% | 12.30% | 31.51% | 23.41% | 20.70% |
Return on Capital Employed (ROCE) | 4.70% | 5.70% | 5.10% | 10.80% | 7.90% | 6.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.81% | 2.40% | 1.77% | 3.38% | 2.60% | 2.05% |
FCF Yield | 1.62% | 0.95% | -1.41% | 2.17% | 1.65% | 1.15% |
Dividend Yield | 0.68% | 0.64% | 0.78% | 1.23% | 1.20% | 0.77% |
Payout Ratio | 65.81% | 28.78% | 90.53% | 29.27% | 29.58% | 53.86% |
Buyback Yield / Dilution | -1.39% | -1.35% | 1.08% | -1.08% | 0.04% | 1.14% |
Total Shareholder Return | -0.70% | -0.71% | 1.86% | 0.15% | 1.24% | 1.92% |